U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07549581) titled 'A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode' on April 17.
Brief Summary: The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple dose oral administration of SEP-380135 in participants with schizophrenia or with a major depressive episode associated with bipolar I or II disorder or major depressive disorder (MDD).
Study Start Date: Nov. 07, 2024
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Major Depressive Disorder (MDD)
Bipolar Disorder
Intervention:
DRUG: SEP-380135
oral capsule.
DRUG: Placebo
Placebo capsule.
...